Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan
Our data suggest that epEVRCTs are common and correlate with better clinical outcomes in la/mUC patients treated with EV, underscoring the importance of proactive EVRCT management to optimize therapeutic benefits.
Authors
- Naotaka Nishiyama
- K. Hashimoto
- Michihiko Kobayashi (ORCID: https://orcid.org/0000-0002-9633-8094)
- H. Kitamura
- Tomokazu Sazuka (ORCID: https://orcid.org/0000-0002-8902-7853)
- Takashi Yoshida (ORCID: https://orcid.org/0000-0003-1119-312X)
- Yoshiyuki Matsui (ORCID: https://orcid.org/0000-0002-2953-7085)
- Shuichi Tatarano (ORCID: https://orcid.org/0000-0003-4224-5084)
- Tadashi Kobayashi (ORCID: https://orcid.org/0000-0002-2001-4464)
- Yasuhiro Shiraishi
- Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
- Akira Yokomizo (ORCID: https://orcid.org/0000-0002-5741-6280)
- Yuki Kita (ORCID: https://orcid.org/0000-0002-6942-9695)
- Junji Watanabe (ORCID: https://orcid.org/0000-0002-6795-2554)
- Yusuke Sugino (ORCID: https://orcid.org/0000-0001-8361-0805)
- Keiichiro Mori (ORCID: https://orcid.org/0000-0002-6147-6569)
- H. Nishiyama
- Hiroyuki Ito (ORCID: https://orcid.org/0000-0001-7398-8943)
- Makito Miyake (ORCID: https://orcid.org/0000-0001-9503-7356)
- Tomoyuki Shibuya
- Nobuyuki Takaoka
- Yuto Matsushita (ORCID: https://orcid.org/0000-0002-8159-9793)
- Tohru Abe (ORCID: https://orcid.org/0000-0003-4868-3237)
- Kei Daizumoto (ORCID: https://orcid.org/0009-0004-9007-435X)
- Kosuke Okasho (ORCID: https://orcid.org/0000-0003-4378-096X)
- Jun Mutaguchi (ORCID: https://orcid.org/0000-0001-8798-2681)
- Atsushi Igarashi (ORCID: https://orcid.org/0000-0002-5143-9764)
- Hikaru Otsuka (ORCID: https://orcid.org/0000-0001-8413-8338)
- Yujiro Takai
- Shigeo Nakanishi
- Toshiaki Mochizuki (ORCID: https://orcid.org/0000-0001-8645-5775)
- Takahiro Anami
- Minoru Kato (ORCID: https://orcid.org/0000-0002-4171-6027)
- Takashi Kawahara (ORCID: https://orcid.org/0000-0001-6494-819X)
- Tetsutaro Hayashi (ORCID: https://orcid.org/0000-0002-1997-488X)
- Isao Kobayashi (ORCID: https://orcid.org/0000-0002-3908-4681)
- Satoru Shimura
- Akane Takahashi (ORCID: https://orcid.org/0000-0002-2585-9271)
- Takanori Hazama
Institutions
- Kagoshima University (JP)
- Yamagata University (JP)
- Hiroshima University (JP)
- Jikei University School of Medicine (JP)
- Kyushu University (JP)
- Sapporo Medical University (JP)
- University of Tsukuba (JP)
- Chiba University (JP)
- Aichi Medical University (JP)
- Mie University (JP)
- Oita University (JP)
- Akita University (JP)
- Hokkaido University (JP)
- Kyoto University (JP)
- Tenri Hospital (JP)
- Hamamatsu University School of Medicine (JP)
- University of the Ryukyus (JP)
- Shizuoka General Hospital (JP)
- Toyooka Hospital (JP)
- Harasanshin Hospital (JP)
- University of the Ryukyus University Hospital (JP)
- Japanese Red Cross Society Wakayama Medical Center (JP)
- Tokyo National Hospital (JP)
- Shiga Medical Center (JP)
- Hakodate National Hospital (JP)
- Kitano Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Municipal Hirakata City Hospital (JP)
- University of Toyama (JP)
- Osaka Metropolitan University (JP)
- Kitasato University (JP)
- Nara Medical University (JP)
- Kobe University (JP)
- University of Yamanashi (JP)
- Tokyo Metropolitan University (JP)
- Yokohama City University (JP)
- Tokushima University (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100094
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders